Answers are grounded in this paper and cite their sources.
Randomized trial investigates cardiac output in pulmonary arterial hypertension patients treated with sotatercept, suggesting unexpected outcomes.
Rationale Sotatercept, a novel activin signaling inhibitor, has demonstrated substantial efficacy in randomized controlled trials for the treatment of pulmonary arterial hypertension (PAH), leading to regulatory approval. Favorable hemodynamics effects were observed, including marked reductions in pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (mPAP) without an increase in cardiac output (CO). The mechanisms underlying the lack of increase in CO and its clinical significance remains unclear. We sought to investigate differential CO responses to sotatercept and identify factors associated with paradoxical CO reduction despite PVR improvement. Methods We conducted a retrospective analysis of patients who underwent right heart catheterization before and after sotatercept initiation. Patients were stratified by CO response (decreased vs maintained/increased). Hemodynamic parameters including mPAP, PVR, right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP) and mixed venous oxygen saturation, and functional assessments (6-minute walk distance [6MWD] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) were compared between groups. Results Fifty patients with PAH (mean age 56±15, 78% females) were included. Follow-up RHC occurred 7 [5 to 9] months after sotatercept initiation. Overall, sotatercept therapy significantly reduced RAP, mPAP and PVR with no changes in CO or PCWP. Thirty patients (60%) exhibited decreased CO (median change -0.8 [-1.1 to -0.5] L/min). These patients were similar in age to those with maintained/increased CO (55±16 vs 58±13 years, p = 0.4) but tended to be more female predominant (87% vs 65%, p = 0.07). Hemodynamics before initiation of sotatercept were comparable except for higher cardiac index in the group with decreased CO (3.1±0.7 vs 2.6±0.7, p = 0.02). Background PAH therapies were similar between the 2 groups. Patients with decreased CO had a markedly attenuated PVR response compared to those with maintained/increased CO (-20% [-37 to -4] vs -46% [-61 to -34], p = 0.001). Both groups achieved similar reductions in mPAP (-14±10 vs -18±11 mmHg, p = 0.3) and RAP (-4.8±5.3 vs -5.5±4.1 mmHg, p = 0.7). Despite differential hemodynamic responses, functional improvements were comparable: 6MWD increased (11±53 vs 28±76 meters, p = 0.5) and NT-proBNP decreased (-207 [-1181 to -40] vs -412 [-1411 to -21] pg/mL, p = 0.7). Changes in prostacyclin dosing were similar between the groups. Conclusions In this cohort, over half of PAH patients exhibited a paradoxical CO reduction following sotatercept initiation, accompanied by an attenuated decrease in PVR. Despite this, clinical markers of disease severity improved, suggesting mechanisms beyond simple afterload-flow relationships. Deeper phenotyping may identify predictors of CO response, elucidate mechanisms and refine therapeutic monitoring in sotatercept-treated PAH patients.
No takes yet. Share an insight, caveat, or question.
Stockdale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: